Business
Navamedic ASA: Imdur® distribution agreement extended to 2032
Navamedic ASA (OSE: NAVA) today announced it has signed a renewed distribution agreement with TopRidge Pharma Limited (TopRidge) for Imdur®, valid until June 2032, including options for new products to be added to the agreement.
About this update from Navamedic Asa
[{"type":"text","content":"OSLO, Norway, April 29, 2025 /PRNewswire/ -- Navamedic ASA (OSE: NAVA) today announced it has signed a renewed distribution agreement with TopRidge Pharma Limited (TopRidge) for Imdur®, valid until June 2032, including options for new products to be added to the agreement.","length":279,"tagName":"p"},{"type":"text","content":""It is a pleasure to announce that we have agreed with our great partner TopRidge Pharma, to revise and renew the distribution agreement for Imdur until 2032. Imdur is our second largest single brand and is currently marketed by us in the Nordics, the Netherlands, the Baltics, Greece and Cyprus. Although there is generic competition in this field, the original product is highly valued by the patients who often stay on the treatment for a long period of time." says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic.","length":551,"tagName":"p"},{"type":"text","content":"Imdur® (isosorbide mononitrate), is a prescription medication used to prevent angina pectoris due to heart disease. It was first launched in Europe in 1985. Navamedic commenced distribution of the product as part of a strategic partnership and long-term distribution agreement with TopRidge Pharma Limited in 2016.","length":314,"tagName":"p"},{"type":"text","content":""Imdur® remains an important product to Navamedic, and we appreciate the efforts made by TopRidge to update the Marketing Authorisations and to secure steady supplies to our markets. With the renewal of this agreement, we look forward to exploring further collaboration opportunities for additional products in the future," Gamborg Andreassen concludes.","length":363,"tagName":"p"},{"type":"text","content":"The effective date of the agreement is 1 January 2025, and the revised terms of the agreement are implemented from this date even though the signature date is 29 April 2025.","length":173,"tagName":"p"},{"type":"text","content":"For further information, please contact:","length":40,"tagName":"p"},{"type":"text","content":"Kathrine Gamborg Andreassen, CEO, NavamedicMobile: +47 951 78 680E-mail: [email protected]","length":97,"tagName":"p"},{"type":"text","content":"Lars Hjarrand, CFO, NavamedicMobile: +47 917 62 842E-mail: [email protected]","length":88,"tagName":"p"},{"type":"text","content":"About Navamedic ","lengt...